Popular vitamins used to keep the skin clear and healthy can be the key to treating CANCER
- Australian scientist develops new way to release chemicals in vitamin E.
- The vitamin is related to the preservation of skin and eyes; boosting immunity
- But one of the chemicals can help treat pancreatic cancer and liver disease
An Australian biotechnology entrepreneur has developed a new way to release powerful chemicals found in vitamin E, which can be used as a treatment for pancreatic cancer and fatty liver.
The chemicals, known as tocotrienols (T3s), can act as anti-inflammatory, as well as prevent scarring and stop the accumulation of fat.
T3s gave excellent performance results when first tested on rats, but were slightly less effective in human trials – until Dr Glenn Tong realized that rats were given a better dose because they chewed the drug before swallowing. has.
“It’s a very direct way to deliver your medicine – it goes directly into your bloodstream without first going through your intestines and liver,” he told AAP.
“The potential is great.”
Dr. Tong decided to try the same thing in humans by developing a way to administer T3s under the tongue.
An Australian entrepreneur for biotechnology has developed a new way of releasing powerful chemicals found in vitamin E, which is known to keep skin and eyes healthy.
His company, Azure Health Technology, has now obtained patents for the delivery technology in major markets, including the US, EU, Japan and China.
It is also about to undergo phase 2 clinical trials of T3s delivered under the tongue to patients with fatty liver disease and pancreatic cancer.
“No one else has ever done that with T3s,” Dr Tong said.
There is no treatment for fatty liver disease, while the currently approved treatments for pancreatic cancer do not improve much in the patient’s quality of life or how long they live.
The results are expected within two years, while the U.S. Food and Drug Administration has indicated it will be willing to speed up the approval of T3 drugs for these diseases.
Dr Tong says T3s can tackle cancer cells by causing cell cycle death and preventing the metastasis that can spread cancer through the body.
The company raised $ 2.25 million to co-finance the two trials through an IPO, and plans to list on the ASX later this month.
Dr Tong says if everything goes according to plan, the medicine could be on the market in three to four years.